**Supplemental file 3**

**Non-rapid eye movement sleep and wake neurophysiology in schizophrenia**

**Authors:** Nataliia Kozhemiako1†, Jun Wang2†, Chenguang Jiang2†, Lei A. Wang3, Guan-chen Gai2, Kai Zou2, Zhe Wang2, Xiao-man Yu2, Lin Zhou3, Shen Li4, Zhenglin Guo3, Robert G. Law1, James Coleman3, Dimitrios Mylonas5, Lu Shen7, Guoqiang Wang2, Shuping Tan6, Shengying Qin7, Hailiang Huang3,8, Michael Murphy4, Robert Stickgold9,10, Dara S. Manoach5, Zhenhe Zhou2•, Wei Zhu2•, Mei-Hua Hall4•, Shaun M. Purcell1,10•\* & Jen Q. Pan3•\*

**Affiliations:**

1. Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School; Boston, USA
2. The Affiliated Wuxi Mental Health Center of Nanjing Medical University; Wuxi, China
3. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard; Boston, USA
4. Department of Psychiatry, McLean Hospital, Harvard Medical School; Boston, USA
5. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School; Boston, USA
6. Huilong Guan Hospital, Beijing University; Beijing China
7. Bio-X Institutes, Shanghai Jiao Tong University; Shanghai China
8. ATGU, MGH, Harvard Medical School; Boston, USA
9. Beth Israel Deaconess Medical Center; Boston, USA
10. Department of Psychiatry, Harvard Medical School; Boston, USA

† - co-first authors; • - co-senior authors

\* - corresponding authors (Jen Q. Pan, jpan@broadinstitute.org ; Shaun M. Purcell, smpurcell@bwh.harvard.edu)

***Supplementary file 3: Significance of group differences between SCZ and CTR adjusted for medication***

|  |  |  |
| --- | --- | --- |
| **EEG metric** | **Antipsychotic medication** | **Adjunctive medication** |
| **Amisulpride****(n=22)** | **Aripiprazole****(n=12)** | **Olanzapine****(n=26)** | **Clozapine****(n=12)** | **Quetiapine Fumarate****(n=6)** | **Risperidone****(n=14)** | **Sedatives and tranquilizers****(n=13)** | **Emotion stabilizers and antiepileptics****(n=17)** | **Anticholinergics****(n=10)** |
| SS Density, 20 channel(s) |  |  |  |  |  |  |  |  |  |
| FS Density, 53 channel(s) |  |  |  |  |  |  |  |  |  |
| SS Amplitude, 49 channel(s) |  |  |  |  |  |  |  |  |  |
| FS Amplitude, 22 channel(s) |  |  |  |  |  |  |  |  |  |
| SS ISA, 34 channel(s) |  |  |  |  |  |  |  |  |  |
| **FS ISA, 1 channel(s)** | n.s. |  | n.s. |  |  |  |  | n.s. |  |
| FS Duration, 35 channel(s) |  |  |  |  |  |  |  |  |  |
| FS Chirp, 20 channel(s) |  |  |  |  |  |  |  |  |  |
| SO Density, 30 channel(s) |  |  |  |  |  |  |  |  |  |
| SO Duration, 36 channel(s) |  |  |  |  |  |  |  |  |  |
| SO Slope, 44 channel(s) |  |  |  |  |  |  |  |  |  |
| SS overlap with SO, 13 channel(s) |  |  |  |  |  |  |  |  |  |
| SO phase angle when SS occur, 2 channel(s) |  |  |  |  |  |  |  |  |  |
| **SO phase angle when FS occur, 2 channel(s)** |  |  | n.s. |  |  |  |  | n.s. |  |
| PSD PC #4 |  |  |  |  |  |  |  |  |  |
| PSI PC #1 |  |  |  |  |  |  |  |  |  |
| **MMN Amplitude, 1 channel(s)** |  |  | n.s. |  |  |  |  |  |  |
| P50 S2/S1 ratio, 10 channel(s) |  |  |  |  |  |  |  |  |  |
| ASSR Power, 15 channel(s) |  |  |  |  |  |  |  |  |  |
| ASSR Phase synchrony, 20 channel(s) |  |  |  |  |  |  |  |  |  |

*For each medication specified in the columns, SCZ patients taking that medication were excluded from the SCZ sample and group differences for each EEG metric at each channel were re-estimated.* ***n.s.*** *indicates that there were no channels with significant differences (unadjusted p<0.01) once subjects taking the corresponding medication were excluded.*